Frontlight ResearchEarly access
Taking people in BulgariaPhase 2
Long-term study of IMVT-1402 in adults with Graves' disease
Tests IMVT-1402 over a longer period in adults with Graves' disease.
Key facts
- Who runs it
- Immunovant Sciences GmbH
- Where
- Dobrich, Plovdiv, Sliven, Smolyan, Sofia, Sofiya, Varna, and Yambol, BulgariaSee the 14 sitesAlso in 10 other countries, 89 sites
- Trial code
- Registry title
- A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 128 people, planned
- Started
- 11 Jun 2026
- Expected to end
- 30 Mar 2030
- Type of study
- Interventional
- Record updated
- 16 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. It follows how well IMVT-1402 works over the long term.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Graves' disease (an overactive thyroid caused by the immune system)
- Earlier treatment
- People must have completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
Main reasons for not taking part
- Stopped the study drug for good during the treatment period of the earlier study
- Met the stopping rules of the earlier study at any time while taking part in it
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503
Who cannot take part
- Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study
This trial is currently available in Bulgaria.
Also in 10 other countries, 89 sites
- Medical Center Viva Phoenix OODDobrich, BulgariaTaking people
- University Multiprofile Hospital For Active Treatment Kaspela EOODPlovdiv, BulgariaTaking people
- University Multiprofile Hospital For Active Treatment Pulmed Ltd.Plovdiv, BulgariaTaking people
- Multiprofile Hospital For Active Treatment Hadji Dimitar OODSliven, BulgariaTaking people
- Medical Center Smolyan Klinikal Research Ltd.Smolyan, BulgariaTaking people
- Alexandrovska University HospitalSofia, BulgariaTaking people
- Kalimat Medical Center Ltd.Sofia, BulgariaTaking people
- Multiprofile Hospital for Active Treatment "Knyaginya Klementina" - Sofia EADSofia, BulgariaTaking people
- University Specialized Hospital For Active Treatment In Endocrinology Akad. Iv. Penchev EADSofia, BulgariaTaking people
- University Multiprofile Hospital For Active Treatment Sofiamed OODSofiya, BulgariaTaking people
- Diagnostic Consultative Center Equita OODVarna, BulgariaTaking people
- Medcenter Nova Clinic Ltd.Varna, BulgariaTaking people
- Medical Centre "Pratia Clinic" EOODVarna, BulgariaTaking people
- Medical Center Berbatov Ltd.Yambol, BulgariaTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of IMVT-1402 as assessed by maintenance of euthyroidism, off ATD, and off IMVT-1402 for 52 weeks in Group A Participants
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
- Plain-language title
- Long-term study of IMVT-1402 in adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 17 November 2026.
- Record updated
- 16 November 2026